Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0A5SA
|
|||
Former ID |
DNCL003785
|
|||
Drug Name |
TAK-272
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 2 | [1] | |
Company |
Takeda
|
|||
Structure |
Download2D MOL
|
|||
Formula |
C27H42ClN5O4
|
|||
Canonical SMILES |
CC(C)CN(C1CC(CNC1)C(=O)N2CCOCC2)C(=O)C3=NC4=CC=CC=C4N3CCCCOC.Cl
|
|||
InChI |
1S/C27H41N5O4.ClH/c1-20(2)19-32(22-16-21(17-28-18-22)26(33)30-11-14-36-15-12-30)27(34)25-29-23-8-4-5-9-24(23)31(25)10-6-7-13-35-3;/h4-5,8-9,20-22,28H,6-7,10-19H2,1-3H3;1H/t21-,22+;/m1./s1
|
|||
InChIKey |
PUXOYQIZZIWCHH-NSLUPJTDSA-N
|
|||
CAS Number |
CAS 1202269-24-6
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Angiotensinogenase renin (REN) | Target Info | Modulator | [2] |
KEGG Pathway | Renin-angiotensin system | |||
Pathwhiz Pathway | Angiotensin Metabolism | |||
Reactome | Metabolism of Angiotensinogen to Angiotensins | |||
WikiPathways | ACE Inhibitor Pathway | |||
Metabolism of Angiotensinogen to Angiotensins |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT02332824) A Phase 2 Dose-finding Study of TAK-272 in Patients With Type 2 Diabetes Mellitus and Microalbuminuria. U.S. National Institutes of Health. | |||
REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033655) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.